In addition, TCS treatment can markedly decrease the expression level of leucine rich repeat containing G-protein-coupled receptor 5 (LGR5) and repress key proteins in the Wnt/beta-catenin signaling pathway to induce apoptosis in glioma cells (Figure 4), thereby inhibiting glioma cell proliferation, invasion and migration [90]. Here, LGR5 is linked to central nervous system cancer.